These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 7963811

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Comparative pharmacokinetics of oxaliplatin (L-OHP) and carboplatin (CBDCA) in mice with reference to circadian dosing time.
    Boughattas NA, Hecquet B, Fournier C, Bruguerolle B, Trabelsi H, Bouzouita K, Omrane B, Lévi F.
    Biopharm Drug Dispos; 1994 Dec; 15(9):761-73. PubMed ID: 7888604
    [Abstract] [Full Text] [Related]

  • 23. Platinum agents in the treatment of osteosarcoma: efficacy of cisplatin vs. carboplatin in human osteosarcoma cell lines.
    Robson H, Meyer S, Shalet SM, Anderson E, Roberts S, Eden OB.
    Med Pediatr Oncol; 2002 Dec; 39(6):573-80. PubMed ID: 12376980
    [Abstract] [Full Text] [Related]

  • 24. Enhanced antitumor activity in mice after administration of thermosensitive liposome encapsulating cisplatin with hyperthermia.
    Iga K, Hamaguchi N, Igari Y, Ogawa Y, Gotoh K, Ootsu K, Toguchi H, Shimamoto T.
    J Pharmacol Exp Ther; 1991 Jun; 257(3):1203-7. PubMed ID: 2046024
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Superselective cisplatin (CDDP)-carboplatin (CBDCA) combined infusion for head and neck cancers.
    Imai S, Kajihara Y, Munemori O, Kamei T, Mori T, Handa T, Akisada K, Orita Y.
    Eur J Radiol; 1995 Dec 15; 21(2):94-9. PubMed ID: 8850500
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Treatment of murine SCC VII tumors with localized hyperthermia and temperature-sensitive liposomes containing cisplatin.
    Nishimura Y, Ono K, Hiraoka M, Masunaga S, Jo S, Shibamoto Y, Sasai K, Abe M, Iga K, Ogawa Y.
    Radiat Res; 1990 May 15; 122(2):161-7. PubMed ID: 2336462
    [Abstract] [Full Text] [Related]

  • 30. Local hyperthermia enhances the effect of cis-diamminedichloro-platinum(II) on nonirradiated and preirradiated rat solid tumors.
    van Bree C, Rietbroek RC, Schopman EM, Kipp JB, Bakker PJ.
    Int J Radiat Oncol Biol Phys; 1996 Aug 01; 36(1):135-40. PubMed ID: 8823268
    [Abstract] [Full Text] [Related]

  • 31. Pharmacokinetics and tissue distribution of cisplatin in nude mice: platinum levels and cisplatin-DNA adducts.
    Johnsson A, Olsson C, Nygren O, Nilsson M, Seiving B, Cavallin-Stahl E.
    Cancer Chemother Pharmacol; 1995 Aug 01; 37(1-2):23-31. PubMed ID: 7497593
    [Abstract] [Full Text] [Related]

  • 32. [Phase I clinical study of combined cisplatin and carboplatin therapy in lung cancer].
    Hayasaka S, Yoshinaga T, Kinuwaki E, Kiyama T, Fujino N.
    Gan To Kagaku Ryoho; 1992 Oct 01; 19(12):2011-6. PubMed ID: 1417008
    [Abstract] [Full Text] [Related]

  • 33. Antitumor effects of three platinum complexes, (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato)-platinum (II) monohydrate (DWA2114R), cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) (CBDCA) and cis-diamminedichloroplatinum(II) (CDDP), in mice.
    Endo K, Akamatsu K, Matsumoto T, Morikawa K, Koizumi M, Mitsui H, Koizumi K.
    Anticancer Res; 1992 Oct 01; 12(1):49-58. PubMed ID: 1567181
    [Abstract] [Full Text] [Related]

  • 34. Impaired hydrolysis of cisplatin derivatives to aquated species prevents energy-dependent uptake in GLC4 cells resistant to cisplatin.
    Pereira-Maia E, Garnier-Suillerot A.
    J Biol Inorg Chem; 2003 Jul 01; 8(6):626-34. PubMed ID: 12756611
    [Abstract] [Full Text] [Related]

  • 35. A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer.
    Steller MA, Egorin MJ, Trimble EL, Bartlett DL, Zuhowski EG, Alexander HR, Dedrick RL.
    Cancer Chemother Pharmacol; 1999 Jul 01; 43(2):106-14. PubMed ID: 9923815
    [Abstract] [Full Text] [Related]

  • 36. Cyclophosphamide-cisplatin versus cyclophosphamide-carboplatin in stage III-IV ovarian carcinoma: a comparison of equally myelosuppressive regimens.
    Edmonson JH, McCormack GM, Wieand HS, Kugler JW, Krook JE, Stanhope CR, Everson LK, Laurie JA, Ebbert LP, Malkasian GD.
    J Natl Cancer Inst; 1989 Oct 04; 81(19):1500-4. PubMed ID: 2674460
    [Abstract] [Full Text] [Related]

  • 37. Comparisons of carboplatin and cisplatin as potentiators of 5-fluorouracil and radiotherapy in the mouse L1210 leukaemia model.
    Dionet CA, Rapp M, Tchirkov A.
    Anticancer Res; 2002 Oct 04; 22(2A):721-5. PubMed ID: 12014642
    [Abstract] [Full Text] [Related]

  • 38. [Pharmacokinetics of new cisplatin analogues in experimental animals].
    Fujita H, Okamoto M, Takao A.
    Gan To Kagaku Ryoho; 1989 Apr 04; 16(4 Pt 2-2):1366-72. PubMed ID: 2658824
    [Abstract] [Full Text] [Related]

  • 39. Antitumor effect of carboplatin combined with hyperthermia on Ehrlich-ascites tumor in vivo.
    Mizuuchi H, Yoshiga K, Sakurai K, Tsumura M, Takada K.
    Anticancer Res; 1996 Apr 04; 16(1):381-7. PubMed ID: 8615640
    [Abstract] [Full Text] [Related]

  • 40. Interaction of cis-diamminedichloro-platinum(II) and its analogues cis-1,1- cyclobutanedicarboxylato(2R)-2-methyl-1,4-butanediammineplatinum(II) and cis-diammine(glycolato)platinum with hyperthermia in vivo.
    Takahashi I, Maehara Y, Kusumoto H, Kusumoto T, Baba H, Kohnoe S, Sugimachi K.
    Oncology; 1996 Apr 04; 53(1):68-72. PubMed ID: 8570136
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.